Other Antidiabetics

High-yield Verified · Oct 2026

Other Antidiabetics are a class of medications used for type 2 diabetes.

Medical view → mechanisms, drug comparisons and Step 1 pharmacology

Pioglitazone makes insulin work better; the α-glucosidase inhibitors slow sugar absorption; the glinides release insulin for a meal; pramlintide, used with mealtime insulin, slows the stomach and quiets glucagon.

How it works in the body

The system involved, what goes wrong, and how the drug and body interact.

01 Four different levers on blood glucose

Pioglitazone, a thiazolidinedione, is an agonist of the nuclear receptor PPAR-γ. It decreases insulin resistance in the periphery and in the liver, so insulin-dependent glucose disposal rises and hepatic glucose output falls. It is not an insulin secretagogue, and it works only when endogenous insulin is present, so it is not for type 1 diabetes or diabetic ketoacidosis. Its full effect is not seen for 6 weeks to 6 months, because it acts by changing gene expression.

Acarbose and miglitol, the α-glucosidase inhibitors, block the brush-border enzymes that split oligosaccharides and disaccharides into glucose; acarbose also inhibits pancreatic α-amylase. Carbohydrate absorption is delayed and the after-meal rise in glucose is smaller. They do not increase insulin secretion. Repaglinide and nateglinide, the glinides, close ATP-dependent potassium channels on β cells and release insulin quickly and briefly, so they are taken just before meals. Pramlintide is an analog of amylin, a hormone co-secreted with insulin; it slows gastric emptying, suppresses glucagon after meals and increases satiety.

Loading diagram…

Where each group acts.

02 Why their risks differ

Pioglitazone causes dose-related fluid retention, most of all with insulin. PPAR-γ activation in the collecting tubules increases sodium reabsorption through the epithelial sodium channel, and the fluid can cause or worsen heart failure — the reason for its boxed warning. Weight gain, edema, fractures in women, and possible bladder cancer are its other label warnings.

The α-glucosidase inhibitors leave undigested carbohydrate in the colon, where bacteria ferment it: flatulence, diarrhea and abdominal discomfort are the commonest effects, and they tend to ease with time. On their own they do not cause hypoglycemia. When hypoglycemia occurs with a sulfonylurea or insulin, it is treated with glucose (dextrose), because the drugs block the breakdown of sucrose.

Glinides cause hypoglycemia, especially if a meal is skipped after a dose, so the dose is skipped with the meal. Pramlintide carries a boxed warning for severe hypoglycemia with insulin, particularly in type 1 diabetes, seen within 3 hours of an injection; the mealtime insulin dose is lowered when pramlintide is started.

Loading diagram…

The hypoglycemia rule on an α-glucosidase inhibitor: give glucose, not table sugar.

Drug names

Generic Brand

pioglitazone Actos

acarbose —

miglitol —

repaglinide —

nateglinide —

pramlintide SymlinPen

* SymlinPen (pramlintide): Drugs@FDA lists the Symlin products as discontinued, although AstraZeneca’s SymlinPen label is current with active NDCs (2026).

Indications

Type 2 diabetes — pioglitazone, acarbose, miglitol, repaglinide or nateglinide, with diet and exercise to improve glycemic control in adults (pioglitazone and the glinides are not for type 1 diabetes or diabetic ketoacidosis, and ketoacidosis is a contraindication to acarbose and miglitol)
Pramlintide (SymlinPen) — added for type 1 or type 2 diabetes in patients who use mealtime insulin and have not reached glucose control despite optimal insulin therapy

Mechanism of action

Pioglitazone is a PPAR-γ agonist that decreases insulin resistance in the periphery and liver, increasing insulin-dependent glucose disposal and decreasing hepatic glucose output; it needs endogenous insulin and does not stimulate insulin secretion. Acarbose and miglitol reversibly inhibit membrane-bound intestinal α-glucosidases (acarbose also pancreatic α-amylase), delaying carbohydrate digestion and glucose absorption and lowering postprandial glucose. Repaglinide and nateglinide close ATP-dependent potassium channels on β cells, depolarizing them so calcium enters and insulin is released; the release is glucose-dependent and diminishes at low glucose. Pramlintide, an amylin analog, slows gastric emptying, reduces the postprandial rise in glucagon and increases satiety.

In plain terms

Each one pulls a different lever: pioglitazone makes insulin work better, acarbose and miglitol slow sugar from meals, the glinides give a quick shot of insulin for a meal, and pramlintide slows the stomach and keeps glucagon down.

Onset

Pioglitazone: maximal glucose lowering takes 6 weeks to 6 months. Repaglinide: peak within 1 hour, taken within 30 minutes before meals. Nateglinide: half-life about 1.5 hours, taken 1–30 minutes before meals.

Peak

—

Duration

—

Therapeutic effects — what you'll see working

Success is lower glucose without harm: fasting and after-meal glucose and the A1c moving toward goal, while weight, edema and liver tests are watched on pioglitazone and glucose is checked often around meals on the glinides and pramlintide.

↓ Fasting and post-meal glucose, ↓ A1c Lipid changes (pioglitazone)

↓ Fasting and post-meal glucose, ↓ A1c: Pioglitazone lowers plasma glucose, plasma insulin and HbA1c by decreasing insulin resistance; its full effect takes 6 weeks to 6 months. The α-glucosidase inhibitors and glinides mainly blunt the after-meal rise.
Lipid changes (pioglitazone): Mean triglycerides fell and HDL cholesterol rose in trials, with no consistent change in LDL or total cholesterol; there is no conclusive evidence of macrovascular benefit.

Adverse effects

Each group’s harms follow its lever: fluid retention (pioglitazone), carbohydrate fermentation in the colon (α-glucosidase inhibitors), insulin release without a meal (glinides), and too little glucose with insulin (pramlintide).

Common Expected

α-Glucosidase inhibitors: flatulence, diarrhea, abdominal pain. Pramlintide: nausea, vomiting, anorexia, headache. Pioglitazone: upper respiratory infection, headache, sinusitis, myalgia.

The α-glucosidase inhibitors’ GI effects come from undigested carbohydrate in the lower gut and usually start in the first weeks and ease with time. Pramlintide is titrated slowly, partly to limit nausea.

Hypoglycemia Report immediately

Glinides can cause hypoglycemia, especially with a skipped meal; pioglitazone, acarbose and miglitol add to the hypoglycemia risk of insulin or a sulfonylurea, and pramlintide to that of insulin.

Glinides are taken before a meal and the dose is skipped if the meal is skipped. Awareness may be blunted by long-standing diabetes, neuropathy, β-blockers or recurrent lows. On acarbose or miglitol, treat lows with glucose (dextrose), not sucrose; severe lows may need IV glucose or glucagon.

Pioglitazone — edema, fractures, bladder cancer, liver, eye Hold & notify

Dose-related edema and weight gain; more fractures in women; possible bladder cancer; rare hepatic failure; macular edema.

Fractures, mostly non-vertebral in the lower limb and distal upper limb, were more frequent in women. Pioglitazone may increase the risk of bladder cancer and is not used with active bladder cancer. Postmarketing hepatic failure, sometimes fatal, has been reported: liver tests are checked before starting and promptly for symptoms of liver injury. Macular edema has been reported, so eye exams and prompt evaluation of visual changes are advised. It may cause ovulation in premenopausal anovulatory women.

Acarbose — liver enzymes; α-glucosidase inhibitors — pneumatosis Hold & notify

Acarbose can raise serum transaminases, rarely with jaundice or fulminant hepatitis; pneumatosis cystoides intestinalis has been reported.

Transaminases are checked every 3 months in the first year of acarbose and periodically after; persistent elevations may call for a lower dose or stopping. Pneumatosis cystoides intestinalis (diarrhea, mucus, rectal bleeding, constipation) means stopping the drug and imaging.

■ Boxed warnings Report immediately

Pioglitazone — congestive heart failure. Pramlintide — severe hypoglycemia with insulin.

Pioglitazone (Actos): thiazolidinediones cause or worsen congestive heart failure in some patients. After starting it, and after dose increases, watch for heart-failure signs (excessive, rapid weight gain, dyspnea, edema). It is not recommended in symptomatic heart failure, and starting it in NYHA class III or IV heart failure is contraindicated. Pramlintide (SymlinPen): use with insulin increases the risk of severe hypoglycemia, particularly in type 1 diabetes, seen within 3 hours of an injection. Patient selection, careful instruction and insulin dose reduction lower the risk.

Interactions

Pioglitazone + gemfibrozil or other strong CYP2C8 inhibitors drug

Raise pioglitazone exposure about 3-fold — the label caps the pioglitazone dose. CYP2C8 inducers (rifampin) lower it.

Pioglitazone + insulin drug

More fluid retention and heart failure, and more hypoglycemia — a lower insulin dose may be needed.

Repaglinide + gemfibrozil (contraindicated) or clopidogrel (avoid) drug

These CYP2C8 inhibitors raise repaglinide exposure many-fold, risking severe hypoglycemia; strong CYP3A4/2C8 inducers lower its effect.

Nateglinide + CYP2C9 inhibitors (amiodarone, fluconazole), NSAIDs, salicylates, MAO inhibitors or non-selective β-blockers drug

May increase hypoglycemia — more glucose monitoring and possibly a lower dose; β-blockers, clonidine and reserpine can blunt warning signs.

Acarbose or miglitol + intestinal adsorbents (charcoal) or digestive enzymes (amylase, pancreatin) drug

May reduce their effect — not taken together. Acarbose may change digoxin bioavailability; miglitol lowers ranitidine and propranolol bioavailability.

Pramlintide + oral medications needing a fast onset (analgesics, antibiotics, oral contraceptives) drug

Slowed gastric emptying delays their absorption — give them 1 hour before or 2 hours after pramlintide. It is not mixed with insulin, and not used with drugs that slow gut motility or nutrient absorption (anticholinergics, α-glucosidase inhibitors).

Pioglitazone, acarbose or miglitol + insulin or a sulfonylurea drug

Additive hypoglycemia — a lower insulin or sulfonylurea dose may be needed.

Contraindications

Each drug’s contraindications guard its own danger — the heart for pioglitazone, the gut for the α-glucosidase inhibitors, and unrecognized lows and gastroparesis for pramlintide.

Pioglitazone — starting it in NYHA class III or IV heart failure

Fluid retention can cause or worsen heart failure (boxed warning).

Pioglitazone — active bladder cancer use caution

It may increase the risk of bladder cancer; with a prior history, benefits are weighed against the unknown recurrence risk.

Acarbose or miglitol — diabetic ketoacidosis; inflammatory bowel disease, colonic ulceration, partial or predisposition to intestinal obstruction; chronic intestinal disease with marked disorders of digestion or absorption; conditions that may worsen with increased intestinal gas

These are on both labels’ contraindication lists; acarbose is also contraindicated in cirrhosis.

Repaglinide — use with gemfibrozil

Gemfibrozil raised repaglinide exposure about 8-fold.

Pramlintide — hypoglycemia unawareness, or confirmed gastroparesis

Both are on the label’s contraindication list: pramlintide adds severe-hypoglycemia risk and slows gastric emptying.

Hypersensitivity to the drug

A contraindication on each label (pramlintide: serious hypersensitivity).

When to hold

Assess before giving — these findings mean hold the dose and act.

Pioglitazone — rapid weight gain, dyspnea or edema

Notify the prescriber: heart failure is evaluated, and stopping or lowering pioglitazone is considered.

Pioglitazone — symptoms of liver injury (fatigue, anorexia, right upper abdominal discomfort, dark urine, jaundice)

Check liver tests promptly; with ALT above 3 times the upper limit, pioglitazone is interrupted and not restarted without another explanation.

Glinide — a meal is skipped

Skip that dose to avoid hypoglycemia.

Pramlintide — the patient is sick and cannot eat, or will eat less than a usual meal

Hold the dose: the label says not to inject pramlintide when a meal is skipped, when the patient is sick and cannot eat a usual meal or cannot eat for a procedure, or when glucose is low; the next dose is taken with the next meal, because eating less raises the risk of severe hypoglycemia.

Labs & levels

Test Therapeutic / normal Toxic / critical

Liver tests (ALT, AST, alkaline phosphatase, bilirubin) Pioglitazone: before starting and promptly for symptoms of liver injury. Acarbose: transaminases every 3 months in the first year, then periodically — —

Blood glucose Frequently when starting pramlintide or a glinide, and when other glucose-lowering drugs are adjusted — —

Nursing considerations

The RN-specific layer — each action paired with the reason it matters.

Administration & safety

Give acarbose or miglitol with the first bite of each main meal.

Why: They work only on carbohydrate eaten with the dose.

Give repaglinide within 30 minutes before a meal and nateglinide 1–30 minutes before; skip the dose if the meal is skipped.

Why: Their short insulin burst without food causes hypoglycemia.

Inject pramlintide before a major meal as a separate injection from insulin — never mixed — and never share a SymlinPen, even with a new needle.

Why: Mixing alters both drugs’ pharmacokinetics, and pen-sharing risks blood-borne pathogens.

Monitoring & at-risk patients

On pioglitazone, weigh the patient and watch for edema, dyspnea and rapid weight gain, especially after starting, after dose increases and with insulin.

Why: Fluid retention can cause or worsen heart failure (boxed warning).

Check liver tests before pioglitazone and promptly if liver-injury symptoms appear; check transaminases regularly in the first year of acarbose.

Why: Hepatic failure has been reported with pioglitazone, and acarbose can raise transaminases.

Before pramlintide, confirm the patient recognizes hypoglycemia and has no gastroparesis; check glucose often as it is started.

Why: Hypoglycemia unawareness and gastroparesis are contraindications, and severe lows occur within 3 hours of an injection.

Patient teaching

On acarbose or miglitol with a sulfonylurea or insulin, keep glucose tablets or gel (dextrose) for lows — not table sugar.

Why: The drugs block sucrose breakdown, so sucrose is unsuitable for rapid correction.

Expect gas and loose stools at first on acarbose or miglitol; they usually ease over weeks.

Why: Undigested carbohydrate is fermented in the colon.

On pioglitazone, report swelling, breathlessness, rapid weight gain, dark urine, jaundice, blood in the urine or vision changes; premenopausal women should know it may restore ovulation.

Why: These flag heart failure, liver injury, bladder cancer or macular edema, and unintended pregnancy can occur.

On pramlintide, keep a fast-acting sugar on hand, take care with driving or machinery in the hours after an injection, and take time-critical oral medicines 1 hour before or 2 hours after it.

Why: Severe hypoglycemia can occur within 3 hours and has caused injuries while driving, and pramlintide delays absorption of oral drugs.

Common questions

What are Other Antidiabetics used for?

Other Antidiabetics are used for type 2 diabetes. Pramlintide (SymlinPen) for added for type 1 or type 2 diabetes in patients who use mealtime insulin and have not reached glucose control despite optimal insulin therapy.

How do Other Antidiabetics work?

What are the serious side effects of Other Antidiabetics?

Watch for glinides can cause hypoglycemia, especially with a skipped meal; pioglitazone, acarbose and miglitol add to the hypoglycemia risk of insulin or a sulfonylurea, and pramlintide to that of insulin; (with pioglitazone) dose-related edema and weight gain; more fractures in women; possible bladder cancer; rare hepatic failure; macular edema; acarbose can raise serum transaminases, rarely with jaundice or fulminant hepatitis; pneumatosis cystoides intestinalis has been reported.

When should a nurse hold Other Antidiabetics, and what safety checks apply?

Pioglitazone — rapid weight gain, dyspnea or edema: notify the prescriber: heart failure is evaluated, and stopping or lowering pioglitazone is considered. Pioglitazone — symptoms of liver injury (fatigue, anorexia, right upper abdominal discomfort, dark urine, jaundice): check liver tests promptly; with ALT above 3 times the upper limit, pioglitazone is interrupted and not restarted without another explanation. Glinide — a meal is skipped: skip that dose to avoid hypoglycemia. Pramlintide — the patient is sick and cannot eat, or will eat less than a usual meal: hold the dose: the label says not to inject pramlintide when a meal is skipped, when the patient is sick and cannot eat a usual meal or cannot eat for a procedure, or when glucose is low; the next dose is taken with the next meal, because eating less raises the risk of severe hypoglycemia.

What labs should be monitored with Other Antidiabetics?

Monitor liver tests (ALT, AST, alkaline phosphatase, bilirubin) and blood glucose.

Sources

Reviewed by Hae Suk Lee, RN

Educational summary for nursing students. Always verify against current prescribing information and your institution's protocols before administering. Not medical advice.